Mild-to-moderate aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) is common and often clinically silent. Higher-degree AR may occur, with significant haemodynamic and clinical consequences. Treatment of this condition is challenging and there are no evidence-based therapeutic options. This image illustrates the successful percutaneous management of clinically relevant paravalvular leaks (PVL) after implantation of the CoreValve bioprosthesis (Medtronic, Minneapolis, MN, USA) with the use of vascular plug devices.
Conflict of interest statement
The authors report no financial relationships or conflicts of interest regarding the content herein.
Figure 1. Examples of successful percutaneous closure of severe paravalvular ...
STATE OF THE ART
Transcatheter treatment for tricuspid valve disease
This State-of-the-Art - by F. Praz et al - reviews the available transcatheter therapies, main criteria for patient and device selection, remaining uncertainties, and future directions
November 19, 2021